In a major shift for the global pharmaceutical industry, Mounjaro - the diabetes and obesity treatment developed by Eli Lily - has officially overtaken Keytruda to become the world’s top-selling medicine. The development highlights the explosive global demand for obesity and diabetes therapies, especially newer GLP-1 and dual-action metabolic drugs that are rapidly transforming healthcare markets worldwide.
According to the latest quarterly pharmaceutical sales data, Mounjaro generated approximately $8.7 billion in revenue during the first quarter of 2026, surpassing Keytruda’s $7.9 billion sales during the same period.
Keytruda, developed by Merck & Co., has dominated the global pharmaceutical market since 2023. The immunotherapy drug, which contains pembrolizumab, is used in the treatment of nearly 22 different cancer types and remains one of the world’s most important cancer therapies.
However, the rapid rise of anti-obesity and diabetes medicines is now reshaping the pharmaceutical landscape.
Also read:Hantavirus Patients Evacuated Across European Ports: How Global Contact Tracing Kicks In During Outbreaks
Mounjaro contains tirzepatide, a next-generation molecule that targets both GLP-1 and GIP receptors in the body. Doctors prescribe it for type 2 diabetes management and weight loss because it helps regulate blood sugar, appetite, and metabolism.
Health experts say the drug’s popularity reflects the growing global burden of obesity and diabetes. According to the World Health Organization, around 890 million adults across the world were living with obesity in 2022, while nearly 590 million adults had diabetes. The increasing focus on metabolic health, weight management, and preventive healthcare has driven demand for GLP-1 therapies to record levels globally.
Experts believe the rapid rise of anti-obesity and diabetes medicines is reshaping the pharmaceutical landscape
India has become one of the fastest-growing markets for Mounjaro. According to Pharmarack data, the medicine became India’s highest-selling drug by value in April 2026 and has consistently remained among the top-selling therapies since its launch in the country in March 2025.
Over the past year, Mounjaro reportedly generated nearly Rs 1,009 crore in domestic sales, reflecting strong demand among Indian patients seeking advanced diabetes and obesity treatments. Doctors say Indian consumers are increasingly willing to invest in premium chronic therapies that offer significant lifestyle and long-term health benefits.
Source: India Latest News, Breaking News Today, Top News Headlines | Times Now
